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Schizophrenia and schizophrenia spectrum
disorders (SSDs) are mental illnesses of
unknown etiology, typically diagnosed in
adolescence or adulthood. With no known
cure, these diseases are frequently associated
with long-term disability and staggering social
and economic costs. Over the past 20 years,
researchers have theorized that exposures that
elevate the risk of later developing schizophre-
nia may occur during the prenatal period. A
current version of the “neurodevelopmental
hypothesis” of schizophrenia states that
gene–environment interactions alter the
structure and function of the developing
brain, contributing to the onset of schizo-
phrenia later in life (Murray and Lewis 1987;
Waddington and Youssef 1987; Weinberger
1987). Although this working hypothesis is
now widely used, the underlying mechanisms
are the subject of ongoing debate. In this
review we consider methods being used to
study the prenatal environment and schizo-
phrenia, particularly the relationship between
prenatal lead (Pb) exposure and schizophrenia.
Early Antecedents 
of Schizophrenia
Schizophrenia is a mental illness that has been
grouped among the psychotic disorders, that
is, those chiefly characterized by delusions,
sensory hallucinations, and severe impair-
ments of speech organization. It has not been
associated successfully with any speciﬁc physi-
cal finding universal to all cases. For some
time, this led researchers to doubt that schizo-
phrenia had any underlying physical cause.
Many sought to find evidence of brain
pathology but were unsuccessful, leading to
the declaration that schizophrenia was the
“graveyard of neuropathologists” (Plum
1972). During 1980s, that belief was gradu-
ally supplanted as subtle physical findings
began to emerge. Neuroimaging techniques
suggested structural changes, such as
increased ventricular volume in the brains of
patients (Kelsoe et al. 1988), and cohort stud-
ies found differences in neuromotor function
and childhood behavior between patients
who developed schizophrenia and the general
population. This seemed to suggest early ori-
gins of the illness, predating clinically deﬁned
disease by decades. Although on brain imag-
ing, certain regional changes such as increased
ventricular and reduced cortical and hip-
pocampal volume have been noted (Halliday
2001), ﬁndings in schizophrenia are compara-
tively subtle. Overall, these indicate mild
structural disarray at the cellular level, changes
in neural density (Chana et al. 2003), and
decreased neuropil (Roberts et al. 1996) along
with altered connectivity in multiple regions
of the brain (Harrison 1999).
Prospective approaches. The use of post-
mortem examination is problematic in studies
of diseases that have early antecedents because
it is difﬁcult to determine whether ﬁndings are
because of underlying dysfunction rather than
degeneration after clinical progression or side
effects of pharmacologic treatment. In the
study of fetal origins of schizophrenia, it is
also difficult to apply the case–control
approach, because reliable evidence of events
that occurred during fetal development can-
not be obtained easily. Prospective techniques
are one potential solution; such studies, based
on cohorts of subjects identified before the
onset of disease and before the exposures
under investigation (e.g., at or before birth)
and followed across the life course, have
become key to investigations of early develop-
mental events in schizophrenia. However,
such investigations are complicated by the
very long latency of the disease, since clinical
onset may not be evident until adolescence or
adulthood, decades after the putative prenatal
exposures. Systems to track subjects, identify
exposures, and diagnose disease must be main-
tained for decades. In addition, large numbers
of subjects are required to accurately assess the
relatively modest increases in risk that any
single factor is likely to contribute to a multi-
factorial disease such as schizophrenia.
Recent investigations have built on these
studies, using prospective cohorts identified
before birth for studies of known or suspected
neurodevelopmental disruptors. Several ascer-
tain prenatal exposure through quantifiable
measurements, for example, analysis of
archived maternal biologic samples collected
before birth. Various hypotheses have been
advanced, and a number of studies have pro-
duced suggestive results. As an example, we
describe one ongoing study that has examined
toxic, nutritional, infectious, and other risk
factors. After describing selected ﬁndings on
infection and nutrition that illustrate the
methods used, we then describe how this
study has been used to investigate prenatal
lead exposure as a risk factor.
The PDS study. The Prenatal Determinants
of Schizophrenia (PDS) study was initiated
in the 1990s. It is based on a cohort of
approximately 20,000 pregnant women
identified in northern California between
1959 and 1966 as part of the Childhood
Health and Development Study (Susser et al.
2000). This study includes aliquots of mater-
nal sera drawn during prenatal visits. These
samples were stored and maintained at
National Institutes of Health facilities, frozen
at –20°C in anticipation of future studies.
They have been used in combination with hos-
pital records and new diagnostic data (van den
Berg et al. 1988).
Cases of schizophrenia and SSDs were
identified from a database of inpatient,
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cohort members with diagnoses indicative of
psychosis or prescriptions for antipsychotic
medication were reviewed, abstracted, and
rated by two psychiatrists for the presence or
absence of psychosis. These ratings were then
used to identify potential cases to be sought for
a thorough diagnostic interview. Ultimately,
71 cases of schizophrenia and SSDs were iden-
tiﬁed. Controls were selected from the cohort
and matched to cases on the basis of several
factors, including date of membership in the
cohort, date of birth, gender, timing of first
maternal blood draw, and the number of
available serum samples (for details see Susser
et al. 2000).
Influenza and markers of infection.
Previous work describing associations
between prenatal exposure to a variety of viral
agents has been considered for some time and
extensively reviewed elsewhere (Crow 1978;
Mednick et al. 1988; Torrey and Peterson
1973). The PDS study is among the first
studies capable of performing serologic
measures for exposure to influenza. For this
analysis in stored maternal serum from cases
and matched controls, the hemagglutination
inhibition test was performed on four anti-
gens of inﬂuenza strains known to be preva-
lent between 1959 and 1966 in northern
California, including A/H2N2/Japan/57, A/
H2N2/Japan/62, A/H2N2/Taiwan/64, and
B/Massachusetts/66. Exposure to influenza
usually results in a rise in antibody titers,
referred to as seroconversion. Typically, sero-
conversion is characterized as a 4-fold rise in
antibody titers taken in serial samples. As most
subjects in this study had single samples taken
within each trimester, a single cutoff level was
sought as a proxy of inﬂuenza exposure during
pregnancy. Validity studies demonstrated that
levels of ≥ 1:20 in a single serum sample were
highly speciﬁc and sensitive.
First-trimester exposure was associated a
7-fold increase in risk of schizophrenia and
SSDs, whereas second- and third-trimester
exposure showed no increase in risk. However,
although first trimester is usually defined as
the period between zero and 90 days after the
last menstrual period (post-LMP), the blood
draws taken in this study only occur as early as
46 days post-LMP. Therefore, ﬁrst trimester
here signiﬁes, in effect, assessment in the latter
part of ﬁrst trimester. Additional analyses were
conducted analyzing exposure during the ﬁrst
and second halves of pregnancy defined as
0–142 days (in effect, 40–142 days post-
LMP) and from 143 days post-LMP until ter-
mination of pregnancy, respectively. Exposure
in the first half of pregnancy conferred a
3-fold increase in risk, whereas no increase was
seen after exposure during the second half of
pregnancy or when second-trimester exposure
was considered.
Although clearly an advance over previous
work, the PDS study has three key limitations.
First, the number of cases of schizophrenia
and SSDs with the required prenatal sera was
small—64 cases and two matched controls per
case. Although the study found a substantial
association between prenatal influenza expo-
sure and schizophrenia, the conﬁdence limits
of this association are wide. Second, inﬂuenza
infection is typically documented by noting an
increase in titers over time, and the measure
used in this study represents a proxy of the
established standard. Third, the increase in
risk does not correspond exactly with previous
ﬁndings concerning timing of exposure. Prior
reports have indicated that second-trimester
exposure is associated with increases in risk,
whereas in this study, exposure during first
trimester and first half of pregnancy confers
risk. Further investigation is required to
explain this difference.
Prenatal maternal nutrition and body
mass index. Nutritional factors has also been
postulated to play a role in the etiology of
schizophrenia. Both lack of speciﬁc micronu-
trients and general nutritional deprivation
have been previously implicated as risk fac-
tors for broad developmental disruption and
for schizophrenia specifically. In one land-
mark study of prenatal nutritional depriva-
tion known as the Dutch Famine Study
(Susser et al. 1998), neurodevelopmental
outcomes were measured after severe caloric
restriction. Rates of schizophrenia approxi-
mately doubled for individuals conceived
under conditions of nutrient deprivation
during early gestation (Susser et al. 1996).
Early gestational exposure to famine con-
ferred risk for schizophrenia, whereas late
gestational exposure did not. Later studies
that extended these ﬁndings to schizophrenia
spectrum personality disorders also showed a
2-fold increase in risk for early gestational
exposure to famine (Hoek et al. 1998). Two
other studies found evidence that low mater-
nal body mass index (BMI) or low birth
weight is associated with schizophrenia
(Done et al. 1991; Wahlbeck et al. 2001).
Recently, high rather than low maternal
BMI has become a focus of concern because
the number of women of reproductive age
with above-average or high BMI has increased
in industrialized societies. The PDS study
used measures of prepregnant maternal
BMI, categorized to low (< 19.9), average
(20–26.9), above average (27–29.9), and high
(≥ 30.0). Compared with average maternal
prepregnant BMI, high BMI was signiﬁcantly
associated with schizophrenia and SSDs in
the adult offspring (relative risk = 2.9; 95%
confidence interval, 1.3–6.6). This finding
was independent of maternal age, parity,
race, education, or cigarette smoking during
pregnancy.
Prenatal Lead Exposure and
Neurodevelopment
For centuries lead has been known as a toxic
agent but only recently has been recognized as
having subtle but significant developmental
effects. McKhann stated in 1926 that the
“manifestations of Pb poisoning usually sub-
side without serious consequences.” In 1943
Byers and Lord (1943) disproved this state-
ment in a follow-up study of 20 children with
documented Pb poisoning. They examined
not only gross neurologic signs but also IQ
scores and academic performance. Although
based on a small sample of convenience, 19 of
the children later exhibited serious difﬁculties
in school. Since these initial studies, prenatal
Pb exposure has been measured using mater-
nal blood Pb (BPb) during pregnancy, neona-
tal BPb, amniotic fluid, and umbilical cord
BPb (Korpela et al. 1986). Comparisons of
maternal and umbilical BPb indicate that
transfer of Pb from maternal to fetal blood
during pregnancy is unimpeded by the pla-
centa. Prospective approaches to Pb exposure
and development have been used in a number
of instances. They have focused primarily on
developmental outcomes such as attention,
academic achievement, and cognition, and
have used maternal blood draws or postnatal
measures in a variety of biologic media
(Pocock et al. 1994). These studies and others
generally have provided strong support for the
role of Pb as a developmental neurotoxin
(Bellinger et al. 1994). However, because they
mostly have followed subjects into or through
childhood, they are not informative regarding
adult-onset disorders such as schizophrenia.
A few modestly sized studies have now
followed subjects through adolescence. In one
example, Needleman and colleagues recruited
312 first- and second-grade children in
Chelsea and Somerville, Massachusetts.
Dentin Pb levels were measured for each sub-
ject (Needleman et al. 1979). This measure
was used to identify high exposure (those with
dentin levels > 20 ppm), moderate exposure
(10–19.9 ppm), and low exposure (< 10 ppm)
(Needleman et al. 1990). Neurobehavioral
testing was conducted at the time of collec-
tion in 1979 (mean age, 7.3 years) and again
in 1988 (mean age, 18.4 years). Dentin Pb is
useful as a measure of exposure averaged over
the age of the tooth, although dentin Pb
levels are associated with dental caries and
fillings (Gil et al. 1996). Results showed an
increased risk of not graduating from high
school among those with increased dentin Pb
levels. Reading difficulties sufficiently severe
to be deﬁned as a disability showed a similar
distribution. Subjects who had been diag-
nosed with clinical Pb poisoning earlier in
the study had the highest percentages of
failure to graduate (42.9%) and reading
disabilities (50%).
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data that show Pb exposure versus juvenile
delinquency at different exposure levels. Based
in Cincinnati, Ohio, the sample of 195 sub-
jects is largely African American, disadvan-
taged, and urban. Using a prospective cohort
with prenatal and postnatal BPb assessments
collected every 3 months until 6.5 years, the
study measures parental and self-report of
delinquent behaviors including drug and alco-
hol use in adolescence. Subjects were given self-
report questionnaires and assessed at 15 and
17 years of age. The results are categorized by
lowest, low, medium, and highest BPb levels.
When prenatal BPb, average childhood BPb,
and 78-month BPb were estimated as predic-
tors of delinquent behavior, increasing concen-
trations were associated with a modest increase
in delinquent acts reported in adolescence.
Prenatal BPb exposure > 10 µg/dL results in an
increase of more than 2.3 delinquent acts com-
pared with exposures ≤ 5 µg/dL. Signiﬁcantly
higher rates of delinquent behavior are related
via a categorical BPb measured prenatally and
at 78 months of age, although not by average
childhood BPb (Dietrich et al. 2001).
Findings on Prenatal Lead
Exposure and Schizophrenia
Many of the effects described in adolescence
after early-life exposure, including decreased
academic attainment, social deficits, and
behavioral difﬁculties are comparable with the
early antecedents of SSDs. Similarly, a num-
ber of factors that have been suggested as
being associated with Pb exposure, such as
urban residence, have also been studied as risk
factors for SSDs. Although the samples from
prospective studies described here do not have
sufﬁcient power to be deﬁnitive, the ﬁndings
are suggestive, and the overall approach that
these studies take may be used as a model.
Principally, the combination of prospective
collection of biologic samples can be com-
bined with longitudinal assessments for the
study of early-life exposures as they relate to
adolescent and adult psychiatric diseases.
Although several techniques are available
for assessing Pb exposure in biologic samples,
the principal one used in studies of prenatal
exposure is direct measurements on maternal
blood. The PDS study has stored sera, not
whole blood, containing the Pb-sequestering
erythrocytes required for direct measurements
in small volumes. Techniques for direct
measurement of Pb could not be employed.
However, a biologic marker of Pb exposure,
δ-aminolevulinic acid (δ-ALA) may be
detected in urine, plasma, and serum using
high-pressure liquid chromatography with
ﬂuorescence detection.
Feasibility studies were conducted to assess
the utility and predictive value of this tech-
nique in small volumes of stored maternal
serum (Opler et al. 2004). It was determined
that second-trimester serum was likely to be
the best indicator of prenatal exposure because
both Pb and corresponding δ-ALA levels are
believed to be relatively stable at midpreg-
nancy. Second-trimester samples were avail-
able for 44 cases and 75 matched controls
(one to two controls per case).
A single 100-µL aliquot of second
trimester serum was made available for each
subject. A concentration of 9.5 ng/mL of
δ-ALA, corresponding to a BPb level of
15 µg/dL, was used as a cut-off value to divide
the sample into exposed and unexposed sub-
jects. Samples were coded and blinded with
respect to case status. Using this approach, Pb
exposure as measured by elevated δ-ALA was
associated with about a 2-fold increase in risk
of SSDs in this sample (odds ratio = 2.43;
95% confidence interval, 0.99–5.96). The
small numbers of subjects contribute to the
wide conﬁdence limits.
Some important limitations should be
noted. First, the use of a biologic marker rather
than direct measurements means that the
observed increase in risk could be mediated by
the effects of Pb on δ-ALA rather than by Pb
exposure directly. Serum δ-ALA itself may be
the exposure of interest. In experimental mod-
els, δ-ALA has been shown to be neurotoxic,
interfering with GABA (γ-aminobutyric acid)
neurotransmission [Emanuelli et al. 2001; also
reviewed by Cory-Slechta (1995)]. Second, the
ﬁndings of this study are also difﬁcult to inter-
pret conclusively because the sample size is
relatively small and the result has a wide conﬁ-
dence interval. We have now obtained permis-
sion to analyze the one other existing data set
of this type with a similar sample size. These
results will be forthcoming.
Future Directions
The use of prospectively collected cohorts in
combination with archived biologic samples is a
proven and powerful method for studying
disease–exposure relationships throughout the
life course. This method has allowed schizo-
phrenia research to move away from less reﬁned
deﬁnitions of prenatal exposure and into inves-
tigations that may someday focus on speciﬁc
molecular agents in causal pathways. This lon-
gitudinal approach was made possible by the
foresight of early generations of researchers in
combination with the efforts of those who suc-
ceed them. The initial results from prenatal
cohort studies are still preliminary, and the
process they describe is still in its infancy. Every
class of candidate exposures will beneﬁt from
continued technical and methodologic reﬁne-
ment. Using infection as an example, those
agents or strains that cause the greatest increases
in risk, speciﬁc physiologic responses to infec-
tion, and the timing of exposure during preg-
nancy may be further investigated. Nutritional
deprivation might also be explored in greater
detail, using methods to study the roles of
individual micronutrients. Finally, chemical
exposures could eventually be examined in
terms of toxicokinetics and mechanisms of
action, allowing proximal effects of exposure to
be teased apart and considered separately from
consequent physiologic responses.
Although life-course epidemiology is
currently yielding important results, it is lim-
ited to the resolution and specificity that
designers of prenatal cohorts create through
the type, frequency, and periodicity of data
collection. Presently, the biology that links
exposures to causal mechanisms is nearly
impossible to study in detail without the use
of experimental models. Basic researchers have
used clinical and neurochemical observations
from humans to develop of animal models of
schizophrenia and are now studying some of
the exposures implicated in epidemiology
using the same techniques. Although animal
models of psychiatric disorders are imperfect
and subject to a number of limitations, they
are useful for testing the biologic plausibility
of new hypotheses generated by epidemiology.
We believe that to reach the goal of effec-
tive prevention of schizophrenia, all available
data on the disorder must be integrated,
including observational and experimental ﬁnd-
ings. Investigators with interdisciplinary train-
ing and who are comfortable with the language
and concepts of study design from the popu-
lation level to the molecular level will play a
crucial role in the future of the ﬁeld.
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